<DOC>
	<DOC>NCT01750788</DOC>
	<brief_summary>This is an international observational study in patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism.</brief_summary>
	<brief_title>Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Female and male patients â‰¥ 18 years of age with a diagnosis of nonvalvular atrial fibrillation who start treatment with rivaroxaban to prevent stroke or nonCNS (Central Nervous System) systemic embolism, and who consent to participate in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Embolism</keyword>
	<keyword>Atrial Fibrillation</keyword>
</DOC>